

AI algorithm accelerates solution for early detection and diagnosis of lung cancer



Opportunity

LungLife AI, a lung cancer diagnostics company, uses liquid biopsy tests that locate signs of cancer using microscopic imaging.

The process involves examining a large number of cells and is prone to false positives – requiring more time from scientists and a longer time for the tests, consequently.



Imagining IT Differently

Persistent Systems partnered with LungLife AI to speed up the analysis time for cancer detection.

The solution uses a novel AI-powered approach for accurate signal detection. The introduction of image processing and machine learning in the process for blood testing to detect signs of cancer.

This makes the solution from Persistent Systems, according to ISG, a standout example of AI driven advances in healthcare.



Future Made Possible

The AI decreased the occurrence of false positives, leading to 70% lesser time spent by scientists analyzing patient samples.

In addition to time of scientists saved due to the solution, it has also helped identify additional signals. This increase in sensitivity has the potential to improve the earlier detection and diagnosis of cancer – a mission that drives LungLife AI.



Persistent

LungLifeAI™

**STANDOUT
CASE STUDY IN**

Americas

**STANDOUT
IN**

**Health and Life
Sciences**